Plain-English translation of NCT04657822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a continuation study for people with sickle cell disease who already completed a previous research trial testing . If you finished that earlier study and the medication was helping you, this study lets you keep taking at the same dose you were receiving. The medication aims to reduce painful crises and complications related to sickle cell disease.
When a helpful treatment is still being studied, patients who benefited from it need a way to continue access while researchers gather more safety information. This study bridges that gap, allowing patients to keep receiving this medication rather than stopping abruptly.
You likely qualify if…
You likely don't qualify if…
You'll continue receiving at the same dose and schedule you were on in your previous study. You'll attend regular visits with your research team to monitor how you're doing and check for any side effects. The study expects to stay open for up to 10 years, but may close sooner if the medication becomes widely available through regular prescription or insurance coverage.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States